Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Anaemia, bones and the quieter complications

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Long before kidney failure, CKD produces a set of complications that come from the hormone and balance jobs of the kidney rather than from waste removal.

Most are treatable, several are easy to miss, and one of them, cardiovascular disease, is what actually kills most people with CKD.

Related pages: Chronic kidney disease

The bottom line

What we know
  • Anaemia in CKD comes mainly from reduced erythropoietin production, often with iron deficiency.
  • Low vitamin D activation and phosphate retention drive secondary hyperparathyroidism and bone disease.
  • Metabolic acidosis is common and treating it slows progression.
  • Cardiovascular disease is the leading cause of death in CKD.
  • Gout is more common in CKD and some treatments interact with kidney function.
What is still open
  • Optimal haemoglobin targets in CKD anaemia.
  • Whether treating mineral and bone disorder improves survival.
  • Why standard cardiac risk tools underestimate risk in CKD.

The story, step by step

  1. 1. Anaemia ()
  2. 2. Bones and vessels ()
  3. 3. Acidosis ()
  4. 4. The heart ()
  5. 5. The rest of the list ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Why kidneys affect red cells

Review of many studies

What happens

Erythropoietin, and iron.

What the research shows

  • Kidneys produce erythropoietin, which signals bone marrow to make red blood cells. Damaged kidneys make less.
  • Anaemia in CKD usually appears from stage 3 onwards and becomes common by stage 4.
  • Iron deficiency is frequently present as well, from poor absorption, inflammation and blood loss, and is checked separately.
  • Treatment starts with iron, often intravenous, because oral iron is absorbed poorly in CKD.
  • Erythropoiesis-stimulating agents are used when iron alone is insufficient, targeting a moderate haemoglobin rather than a normal one, because trials found harm from aiming too high.
  • Newer oral drugs, HIF prolyl hydroxylase inhibitors, offer an alternative in some settings.

Why it matters

Treating CKD anaemia improves energy and quality of life measurably, and it is among the most under-recognised causes of fatigue in this group.

What's still uncertain

  • The optimal haemoglobin target.
  • The long-term safety of the newer oral agents.

Read more

Next: Bones and vessels

Part 2 of 5

CKD mineral and bone disorder

Review of many studies

What happens

One process with three consequences.

What the research shows

  • Failing kidneys cannot activate vitamin D properly, so calcium absorption falls, and they cannot excrete phosphate, so it accumulates.
  • Both changes drive the parathyroid glands to overproduce parathyroid hormone, called secondary hyperparathyroidism.
  • Sustained high parathyroid hormone pulls calcium out of bone, weakening it and raising fracture risk.
  • The calcium and phosphate released deposit in blood vessels and heart valves, stiffening them. This vascular calcification is a major contributor to cardiovascular risk in CKD.
  • Monitoring involves calcium, phosphate, parathyroid hormone and vitamin D, usually from stage 3b onwards.
  • Treatment includes dietary phosphate control, phosphate binders, vitamin D analogues and, in some cases, drugs that directly suppress parathyroid hormone.

Why it matters

Bone disease and heart disease in CKD are two faces of the same mineral problem, which is why phosphate is treated more seriously than its symptoms would suggest.

What's still uncertain

  • Whether treating these markers improves survival.
  • The best parathyroid hormone target range.

Read more

Next: Acidosis

Part 3 of 5

The one that gets overlooked

Review of many studies

What happens

Treatable, and it slows progression.

What the research shows

  • Kidneys excrete acid and regenerate bicarbonate. As function declines, acid accumulates and blood bicarbonate falls.
  • Chronic metabolic acidosis causes muscle breakdown and weakness, worsens bone disease and raises potassium.
  • It is also associated with faster CKD progression.
  • Treatment with oral sodium bicarbonate is inexpensive and raises bicarbonate into the normal range.
  • Trials suggest correcting acidosis slows the decline in kidney function and improves nutritional status, though the evidence base is still growing.
  • Fruit and vegetable intake reduces acid load as well, with the caveat that potassium needs watching.

Why it matters

Bicarbonate is one of the cheapest interventions in CKD, it appears on routine blood tests, and it is frequently left untreated.

What's still uncertain

  • How strong the evidence for bicarbonate on progression really is.
  • The optimal target bicarbonate level.

Read more

Next: The heart

Part 4 of 5

What most people actually die of

Review of many studies

What happens

Risk that standard tools underestimate.

What the research shows

  • Cardiovascular disease is the leading cause of death in CKD, and risk rises steeply as eGFR falls and albuminuria increases.
  • CKD causes heart problems through several routes at once: high blood pressure, fluid overload, anaemia, vascular calcification, inflammation and left ventricular thickening.
  • Standard risk calculators underestimate risk in CKD, because they were developed in populations without it.
  • Statins reduce cardiovascular events in CKD not on dialysis. The benefit is less clear once dialysis has started.
  • SGLT2 inhibitors reduce heart failure hospitalisation as well as slowing kidney decline, which is part of why they are now standard.
  • Smoking cessation, blood pressure control and physical activity matter at least as much here as any kidney-specific treatment.

Why it matters

Treating CKD as a kidney problem alone misses the most likely outcome. It is at least as much a cardiovascular condition.

What's still uncertain

  • Why statins lose benefit on dialysis.
  • How to build better risk prediction tools for CKD.

Read more

Next: The rest of the list

Part 5 of 5

Gout, itch, sleep and infection

Review of many studies

What happens

Common, treatable, rarely raised.

What the research shows

  • Gout is more common in CKD because urate is cleared by the kidney, and attacks are often treated badly because NSAIDs and colchicine both need care in CKD.
  • Persistent itch, uremic pruritus, affects many people with advanced CKD, often severely, and specific treatments exist.
  • Sleep problems, restless legs and sleep apnea are all more frequent and all treatable.
  • Infection risk is higher, which is why influenza, COVID-19, pneumococcal and hepatitis B vaccination are recommended, with hepatitis B given earlier because the immune response is better at higher eGFR.
  • Malnutrition and muscle loss develop in advanced CKD and predict worse outcomes.
  • Cognitive impairment is more common, driven partly by shared vascular risk.

Why it matters

Several of these are asked about only if the patient raises them, and they affect daily life more than the eGFR number does.

What's still uncertain

  • Which treatments work best for uremic itch.
  • How to manage gout safely at low eGFR.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.